Engineering nanotransporters demonstrates effective nuclear delivery in prostate cancer, suggesting novel treatment paths.
Polypeptide modular nanotransporters (MNTs) were engineered as a targeted delivery platform for prostate cancer cells. The constructs integrate a ligand module to facilitate specific cellular binding and internalization, and a nuclear localization signal (NLS) to enable subsequent nuclear translocation. Two distinct ligand modules were utilized: (a) a nanobody targeting prostate-specific membrane antigen (anti-PSMA) and (b) a gastrin-releasing peptide (GRP) fragment targeting the GRP receptor (GRPR). It was shown that all modules within MNT-antiPSMA and MNT-GRP retained their functional properties. The MNT-antiPSMA construct demonstrated the capacity to accumulate specifically in the nuclei of prostate cancer cells with both low and high PSMA expression. Conversely, MNT-GRP exhibited selective nuclear entry exclusively in cells characterized by high GRPR expression.
No takes yet. Share an insight, caveat, or question.
Khramtsov et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: